ICICI Securities has raised its rating on GlaxoSmithKline Pharmaceuticals to Add from Hold with a new target price of Rs 2250. GSK Pharma’s earnings are expected to see a CAGR of 15.3% over FY24-27. The company has an asset-light and cash-rich balance sheet, which could improve its return on equity and return on capital employed.
Buy Genus Power Infrastructures; target price Rs 380: Axis Securities
Axis Securities recommends buying shares of Genus Power Infrastructures with a revised target price of Rs 380. Genus Power reported a total income of Rs 617.06 crore for the quarter ended December 2024, showing significant growth. The company is expanding its capacity and expects to maintain a strong financial performance in the coming years.
Zomato shares in focus after launch of AI-backed customer support platform Nugget
Zomato’s CEO Deepinder Goyal has introduced Nugget, an AI-supported customer support platform for its food delivery, Blinkit, and Hyperpure segments. Developed over three years, Nugget manages over 15 million interactions monthly and is open to global businesses. Zomato plans to rebrand as Eternal Ltd, consolidating its four main businesses under this new name.
Paytm shares in focus after partnering with SBI MF to launch Rs 250 SIP
Paytm has partnered with SBI Mutual Fund to launch the JanNivesh ₹250 SIP initiative. This scheme aims to promote financial inclusion by enabling small, regular investments. It supports the Government of India’s vision for economic growth and anticipates growing the mutual funds market significantly.
Dip in M&M shares 1-2-day affair; consumer discretionary stocks to pip staples over 6-12 months: Amnish Aggarwal
M&M shares might dip momentarily, but their medium-term outlook remains positive with robust performance in the auto sector. Pharma, particularly generics, biosimilars, and CDMO, is expected to do well. Consumer stocks poised for growth, especially discretionary spending, will benefit from reduced income tax and monsoons, bolstering demand in Q2 onwards.
Glenmark Pharma shares in focus as company swings back to profit in Q3
Glenmark Pharmaceuticals reported a net profit of Rs 348 crore for Q3FY25, a significant turnaround from a Rs 351 crore loss in the previous year. Revenue increased by 35% YoY to Rs 3,388 crore. Strong performance in the India and Europe markets contributed to the growth.
Betting on these 4 sectors in a nervous market: Shibani Sircar Kurian
Shibani Sircar Kurian of Kotak Mahindra Asset Management highlights that large private and select public sector banks, the healthcare sector, technology sector, and discretionary consumption brands focused on rural and middle-class segments show promising growth. Financial stability, earnings growth in healthcare, and technology advancements are key positive indicators amidst market volatility favoring large-cap investments.
Death Crossovers: These 3 stocks signal further bearishness on Feb 17
Concord Biotech, Natco Pharma among 10 smallcap stocks that crashed up to 41% this week
Here’s a look at the top 10 worst-performing stocks from the BSE Smallcap index during the week
FPIs net sell domestic equities worth Rs 21,272 crore so far in February
Foreign Portfolio Investors (FPIs) have been net sellers of Indian equities, offloading Rs 21,272 crore in February and Rs 99,299 crore in 2025. Despite positive developments in the Indian market, factors such as high US bond yields and slow corporate sales growth in India have driven this trend.
